贝伐单克隆抗体在肾细胞癌治疗中的应用进展  

Advances in Application of Bevacizumab in Renal Cell Carcinoma Treatment

作　　者：王宗喜[1] 肖硕[2] 文九芳[1] 

机构地区：[1]荆州市第一人民医院药学部,湖北荆州434100 [2]华中科技大学同济医学院附属荆州医院药学部,湖北荆州434020

出　　处：《医学综述》2013年第10期1780-1781,1790,共3页Medical Recapitulate

摘　　要：肾细胞癌是常见的泌尿系统恶性肿瘤,在原发性肾肿瘤中占据首位。传统的主要治疗方法为手术治疗、放射疗法等,效果均不甚理想。分子靶向制剂是一类新型的针对癌症发生的特异性分子为治疗靶点的分子靶向药物,可针对在肿瘤发生中起关键作用的靶分子及其调控信号转导通路,增强抗癌治疗的特异性,在临床上的应用日趋广泛,该文新型分子靶向制剂———贝伐单克隆抗体在肾细胞癌治疗中的应用进展进行综述。Renal cell carcinoma,also known as kidney cancer,is a common malignant tumor of the urinary system,which ranks the first among the primary renal tumors.The main treatments are surgical intervention,radiation-therapy and so on,but the effect is not very satisfactory.Molecular targeting agents is a new class for cancer-specific molecular targeted drugs,and it can target at the molecules which play important roles in tumorigenesis its regulational signal transduction pathways,and enhance anti-cancer treatment specificity.The applications of molecular targeted agents are increasingly widespread,and here is to make a review on the recent advances in application of a new molecular targeted agent-Bevacizumab in renal cell carcinoma treatment.

关 键 词：肾细胞癌 分子靶向制剂 贝伐单抗 

分 类 号：R737.11[医药卫生—肿瘤]